Hart Biologicals celebrated its first year under new ownership with exciting plans to further develop its international presence.
Landspitali, the National University Hospital of Iceland, note major difference on using Hart Biological’s new Fiix™ test.
The new range of MEA platelet aggregation reagents is complete and now available as fully compliant IVD products.
The T-TAS-01 is now available with defined measurement parameters to detect abnormal primary haemostatic function.
The International Society on Thrombosis and Haemostasis (ISTH) has converted the leading conference in thrombosis into a digital opportunity for health professionals to immerse themselves in science and education.
Hart Biologicals is pleased to announce the availability of The Fiix™ Test as a fully validated and compliant IVD product.
As the fight against COVID-19 continues around the world and the lockdown measures here in the UK start to be relaxed very slowly, all businesses face the challenge of how to get back on track.
Hart Biologicals is sad to hear of the recent passing of Professor Leon Poller, former Consultant Haematologist at the Withington Hospital, Manchester.
As the coronavirus pandemic continues, a recent article from the BBC shows medical experts confirming up to 30% of patients who are seriously ill with COVID-19 are developing thrombosis.
With the diversity and availability of POCT continuing to rise, a new generation of tests is breaking down the barriers between laboratories and patients.
Hart Biologicals has recently announced the addition of its sixth product, Arachidonic Acid MEA, to its MEA range of platelet aggregation testing reagents.
Hart Biologicals is continuing to get supplies of its products to partners overseas, as the UK enters a further period of restrictions due to the coronavirus pandemic.